Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.20
At close: Jun 24 EDT
$3.24
0.041.25%
Pre-Market: 6:33 PM EDT
Comments
Loading...
Cardiff Oncology Analyst Ratings and Price Targets | NASDAQ:CRDF | Benzinga
Cardiff Oncology Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Cardiff Oncology Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
HC Wainwright & Co.
Piper Sandler
HC Wainwright & Co.
Craig-Hallum
1calculated from analyst ratings
Analyst Ratings for Cardiff Oncology
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/24/2025 | Buy Now | — | Jefferies | Maury Raycroft33% | → $3.5 | Initiates | → Hold | Get Alert |
| 05/09/2025 | Buy Now | — | HC Wainwright & Co. | Robert Burns45% | $17 → $18 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | — | HC Wainwright & Co. | Robert Burns45% | $13 → $17 | Maintains | Buy | Get Alert |
| 12/13/2024 | Buy Now | — | Piper Sandler | Joseph Catanzaro44% | $7 → $10 | Maintains | Overweight | Get Alert |
| 11/08/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju44% | $14 → $13 | Maintains | Buy | Get Alert |
| 09/06/2024 | Buy Now | — | Craig-Hallum | Albert Lowe36% | → $8 | Initiates | → Buy | Get Alert |
| 05/06/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju44% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju44% | $12 → $14 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | — | Piper Sandler | Joseph Catanzaro44% | $5 → $7 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju44% | $13 → $12 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju44% | $14 → $13 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju44% | $15 → $14 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju44% | → $15 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju44% | $14 → $15 | Maintains | Buy | Get Alert |
| 09/16/2022 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju44% | $22 → $14 | Maintains | Buy | Get Alert |
| 09/13/2022 | Buy Now | — | Piper Sandler | Joseph Catanzaro44% | $7 → $5 | Maintains | Overweight | Get Alert |
| 08/29/2022 | Buy Now | — | Baird | Joel Beatty68% | $9 → $6 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Cardiff Oncology (CRDF) stock?
The latest price target for Cardiff Oncology (NASDAQ:CRDF) was reported by Jefferies on June 24, 2025. The analyst firm set a price target for $3.50 expecting CRDF to rise to within 12 months (a possible 8.02% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cardiff Oncology (CRDF)?
The latest analyst rating for Cardiff Oncology (NASDAQ:CRDF) was provided by Jefferies, and Cardiff Oncology initiated their hold rating.
When was the last upgrade for Cardiff Oncology (CRDF)?
There is no last upgrade for Cardiff Oncology
When was the last downgrade for Cardiff Oncology (CRDF)?
There is no last downgrade for Cardiff Oncology.
When is the next analyst rating going to be posted or updated for Cardiff Oncology (CRDF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiff Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiff Oncology was filed on June 24, 2025 so you should expect the next rating to be made available sometime around June 24, 2026.
Is the Analyst Rating Cardiff Oncology (CRDF) correct?
While ratings are subjective and will change, the latest Cardiff Oncology (CRDF) rating was a initiated with a price target of $0.00 to $3.50. The current price Cardiff Oncology (CRDF) is trading at is $3.24, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
